NSE: CAPLIPOINT · 29 October 2026
- Caplin Point Laboratories Ltd. (CAPLIPOINT) inched higher today, gaining 0.56% to settle at ₹2,376.10 compared to its previous close of ₹2,362.80. The stock oscillated within a day's range of ₹2,344.10 and ₹2,409.80, opening slightly lower at ₹2,358.40.
- Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of ₹4 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.
- Trading volume was 0.77 times the 20-day average daily volume.
Why is Caplin Point Laboratories share price rising on 29 October 2026?
Caplin Point Laboratories Ltd. (CAPLIPOINT) inched higher today, gaining 0.56% to settle at ₹2,376.10 compared to its previous close of ₹2,362.80. The stock oscillated within a day's range of ₹2,344.10 and ₹2,409.80, opening slightly lower at ₹2,358.40.
The broader market and sector benchmarks displayed positive momentum during the session, with the Nifty advancing 1.05% and the Nifty Pharma sector index gaining 0.64%. Caplin Point's modest 0.56% gain kept pace with the broader pharmaceutical sector's performance, though it trailed the broader Nifty benchmark. Over a 5-day trading window, the stock has risen 5.65%, while maintaining a 20-day return profile of -13.41%.
On the corporate front, while no single new price-sensitive announcement was released today to directly explain the price action, recent company filings show operational progress, including the voting results of its 35th Annual General Meeting held on 25 September 2026 where shareholders approved a final dividend of ₹4 per equity share alongside key managerial re-appointments. Additionally, earlier in September, subsidiary Caplin One Labs received GMP compliance certification from INVIMA, providing broader context to the company's export and regulatory footprint.
85,348 shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 1.11 lakh shares (0.77 times). The five-day average daily volume was 68,944 shares. Separately, the NSE report for 28 October 2026 showed 19,869 shares delivered, representing 50.32% of that day’s traded volume. The same report recorded 7,977 trades.
With no direct catalyst published today, the 0.56% gain aligns with steady participation in line with the Nifty Pharma sector advance of 0.64%, alongside a moderate rebound following recent 20-day weakness.
Latest Company Developments
Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of ₹4 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.
Confirms formal shareholder approval for capital returns and leadership continuity for the pharmaceutical exporter.
Caplin One Labs Limited, a subsidiary company, received Good Manufacturing Practices compliance certification from INVIMA. This regulatory clearance strengthens the company's standing and export capabilities in regulated international markets.
Expands compliance credentials for manufacturing facilities supporting international market expansion.
Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.
Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2026, recommended Final Dividend of Rs. 4 per equity share.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 1.64% on 30 September 2026. This compares with 2.03% on 30 June 2026, a change of -0.39 percentage points.
The filing reported 20 MF/UTI holders.
What to Watch Next
- Execution of international regulatory approvals and subsequent export dispatch data from subsidiaries like Caplin One Labs and Caplin Steriles.
- Delivery volume trends and cash participation relative to the 20-day average volume.
- Upcoming financial results and commentary on margin performance across Latin American and emerging markets.
More Caplin Point Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Caplin Point Laboratories company news?
Caplin Point Laboratories submitted the scrutinizer report and voting results for its 35th Annual General Meeting held on 25 September 2026. Shareholders successfully approved the adoption of standalone and consolidated financial statements, final dividend of ₹4 per equity share, and various managerial appointments including Dr. Sridhar Ganesan as Managing Director.
How strong was Caplin Point Laboratories’s trading volume?
85,348 shares traded, 0.77 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.